Ernexa Therapeutics Inc. (ERNA)
NASDAQ · Manufacturing · Pharmaceutical preparations
ERNA price, last 12 months
Key stats
- Previous close
- $3.62
- Open
- $3.73
- Day range
- $3.40 – $3.85
- 52-week range
- $3.18 – $71.50
- Volume
- 21.4K
- Avg volume (20 days)
- 45.6K
- Market cap
- $4.0M
Performance
Technicals and fundamentals
About Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $4.0M